Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia.

Background: To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia.

Methods: The study consists of 180 patients, aged 40-75 years, with hyperlipidemia. All patients were divided into two equal groups: patients with different SLCO1B1 (521CC, 521CT and 521TT) and MDR1 (3435CC, 3435TC and 3435TT) genotypes.

Ipidacrine in combination therapy regimens of functional constipation.

Aim: Analysis of the treatment response rates of different therapy regimens of functional constipation, including Ipidacrine, a cholinesterase inhibitor, based on assessment of adaptation and compensatory mechanisms in the therapy forecast.

Materials And Methods: 77 functional slow-transit constipation patients were examined after therapy regimens of functional constipation, the mean age is 44.30±14.

Timing of treatment initiation in West's syndrome.

Background: Infantile spasms (called the West's Syndrome) represent a severe epileptic syndrome which is characterized by a peculiar type of epileptic seizures, spasms, and by electroencephalographic (EEG) abnormalities often called hypsarrhythmia [1]. Infantile spasms are usually resistant to conventional antiepileptic drugs (AEDs) and adrenocorticotrophic hormone (the synthetic analog - tetracosactide) has been the preferred treatment since 1958. The evidence for other antiepileptic drugs is extremely limited compared with vigabatrin.

[Fever-induced refractory epileptic encephalopathy of children].

Fever-induced refractory epileptic encephalopathy of school-age children is a rare epileptic syndrome that causes difficulties in diagnosis at the initial stage of disease. It is characterized by sudden onset with multifocal refractory status epilepticus in previously healthy children with normal development. Later, children suffer from resistant focal epilepsy in the combination with cognitive deficit and behavioral difficulties.

[Optimization of treatment focal forms of epilepsy in young children].

A clinical trial included 30 children, aged from 24 to 46 months, stratified into two groups on the basis of clinical-instrumental data: 22 (73%) patients with symptomatic focal epilepsy and 8 (27%) patients with cryptogenic (possibly symptomatic) focal epilepsy. Topamax (topiramate) was used as mono- (8 children) and combined (22 children) therapy. Mean treatment dose was 5,9 mg/kg per day.